IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4424
Positioning
Market Dominance
Finance, Insurance, And Real Estate
Trading
$504M
Bihua Chen
We are a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. Our executive offices are located at 200 Clarendon Street, 52nd Floor, Boston, MA.
Headcount
—
HQ Base
BOSTON, Massachusetts
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$SII SPROTT INC. | 75 | 91 | 87 | 98 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PUK PRUDENTIAL PLC | 73 | 88 | 97 | 80 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$NMR NOMURA HOLDINGS INC | 72 | 81 | 92 | 87 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PSLV Sprott Physical Silver Trust | 69 | 82 | 80 | 98 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$UFCS UNITED FIRE GROUP INC | 68 | 81 | 93 | 76 | 5.0x | 3.5x | 13.2% | 4.1% | 99.9% | 14.7% | 11.1% | 9.2% | 2.1% | 16.0x | $775M | VS | |
$SLF SUN LIFE FINANCIAL INC | 68 | 83 | 95 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CBOE Cboe Global Markets, Inc. | 68 | 75 | 63 | 77 | 21.3x | 15.7x | 24.0% | 13.7% | 41.7% | 32.4% | 26.4% | 8.2% | 1.1% | 30.0x | $25.7B | VS | |
$VTMX Vesta Real Estate Corporation, S.A.B. de C.V. | 67 | 69 | 77 | 80 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$PHYS Sprott Physical Gold Trust | 67 | 64 | 82 | 91 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$GLDM World Gold Trust | 66 | 54 | 85 | 92 | 11.3x | 11.3x | - | 20.9% | 100.0% | 97.1% | 554.8% | -19.0% | 0.0% | - | $32.0B | VS | |
$BBOT Helix Acquisition Corp. II | 31 | 22 | 27 | 43 | - | - | -8.9% | -8.2% | 100.0% | -97910.2% | 120300.6% | - | 0.0% | 9.0x | $504M | ||
| SECTOR BENCH | - | - | - | - | - | 11.9x | 7.8x | 9.0% | 1.3% | 77.7% | 18.1% | 21.9% | 10.7% | 2.0% | 0.5x | - | REF |
Helix Acquisition Corp. II (BBOT) receives a "Avoid" rating with a composite score of 31.4/100. It ranks #4424 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Finance, Insurance, And Real Estate sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for BBOT.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 22 | 4 | +18ALPHA |
| MOMENTUM | 43 | 43 | 0NEUTRAL |
| VALUATION | 27 | 19 | +8ALPHA |
| INVESTMENT | 25 | 17 | +8ALPHA |
| STABILITY | 36 | 29 | +7ALPHA |
| SHORT INT | 27 | 14 | +13ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -8.9% (sector 9.0%)
GM 100% vs sector 78%, OM -97910% vs sector 18%
Capital turnover N/A
Rev growth N/A, 2yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Helix Acquisition Corp. II (BBOT) as Avoid with a composite score of 31.4/100 at a current price of $10.39. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
Helix Acquisition Corp. II holds a top-quartile position (#0 of 50) within the Finance, Insurance, And Real Estate sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 31.4/100 places it at rank #4424 in our full universe.
No Moat
Medium
Poor
Fair Value
Gross margins of 100% signal strong pricing power.
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
Helix Acquisition Corp. II represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags Helix Acquisition Corp. II with an Avoid rating, assigning a composite score of 31.4/100 and 1 out of 5 stars. Ranked #4424 of 7,333 stocks, BBOT falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
Helix Acquisition Corp. II registers a weak quality score of just 22/100, indicating significant profitability challenges. The company reports a return on equity of -8.9% (sector avg: 9.0%), gross margins of 100.0% (sector avg: 77.7%), net margins of 120300.6% (sector avg: 21.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
BBOT registers a value score of just 27/100, suggesting the stock trades at a significant premium to its fundamental metrics. Key valuation metrics include a P/B ratio of 1.79x. High-premium valuations like this require strong future execution to avoid multiple compression, and downside risk is elevated if growth disappoints.
Helix Acquisition Corp. II's investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -8.2% (sector: 1.3%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
BBOT is currently showing below-average momentum at 43/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.26 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
BBOT's stability score of 36/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.26 and a debt-to-equity ratio of 9.00x (sector avg: 0.5x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Helix Acquisition Corp. II's short interest score of 27/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 9.00x), small-cap liquidity risk. At $504M (small-cap), BBOT carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Helix Acquisition Corp. II is a small-cap company in the Finance, Insurance, And Real Estate sector, ranked #0 of 50 in its sector (100th percentile) and #4424 of 7,333 overall (40th percentile). Key comparisons include ROE of -8.9% trailing the 9.0% sector median and operating margins of -97910.2% below the 18.1% sector average. This top-quartile standing reflects exceptional competitive strength relative to Finance, Insurance, And Real Estate peers.
While BBOT currently exhibits a AVOID profile, superior opportunities exist within the FINANCE, INSURANCE, AND REAL ESTATE sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Finance, Insurance, And Real Estate Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (22) would have the largest impact on the composite score.
ROE 199% BELOW SECTOR MEDIAN
Gross Margin 29% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 539848% BELOW SECTOR MEDIAN
Pre-Market Stock Futures: Futures are trading higher after a stellar and surprising January jobs report as we get to the middle of the trading week. While the Dow Jones Industrial Average managed a winning day, closing up 0.20% at 50,188, the disappointment over the December retail sales report hung over the market like a sword ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: BP Plc., Cloudflare, Dick’s Sporting Goods, Mattel, Noble Corp., Qualcomm, Tyler Technologies, XPO, and M
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in two investor conferences in the upcoming months. Details of the company’s participation are as follows: Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation: Wednesday, February 25, 2026, at 10:40 a.m. E
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026. The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares of BB
Here are the biggest calls on Wall Street on Wednesday.
Stock performance snapshot BridgeBio Oncology Therapeutics (BBOT) has caught investor attention after a recent 12.2% one-day move, adding to gains of 10.6% over the past week and 11.6% over the past 3 months. With the stock last closing at US$12.62 and a year-to-date return of 2.7%, the company’s profile as a clinical-stage biotech with several KRAS-focused programs in Phase I trials is again in focus for traders and longer term holders. See our latest analysis for BridgeBio Oncology...
Above 50MA
37.18%
Net New Highs
+51081